Intervention
SHR-1210
ClinicalTrials.gov intervention label
Clinical trials
15 showna Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung CancerNCT04790539 · 2021-04-01
UNKNOWNCamrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNCT04506242 · 2020-09-15
UNKNOWNApatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCNCT04133337 · 2019-11-01
UNKNOWNA Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLCNCT04108013 · 2019-10-08
UNKNOWNPhase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerNCT03777124 · 2019-07-11
TERMINATEDA Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCNCT03666728 · 2018-11-30
TERMINATEDA Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCNCT03668496 · 2018-11-09
UNKNOWNA Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCNCT03601598 · 2018-07-30
UNKNOWNA Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLCNCT03557411 · 2018-07-09
UNKNOWNAnti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCNCT03527251 · 2018-05-15
UNKNOWNSHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyNCT03417895 · 2018-04-20
COMPLETEDA Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBCNCT03394287 · 2018-01-10
COMPLETEDA Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCNCT03134872 · 2017-05-12
COMPLETEDA Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCNCT03085069 · 2017-05-03
UNKNOWNA Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)NCT03083041 · 2017-03-13
COMPLETEDCommon conditions
Carcinoma, Non-Small-Cell Lung3Lung Neoplasms3PD-1 Antibody3Carcinoma, Bronchogenic2Chemotherapy Effect2Lung Diseases2Neoplasm, Bronchial2Non-Small-Cell Lung Cancer2NSCLC2Respiratory Tract Disease2Thoracic Neoplasms2Breast Cancer1CRC1Extensive Stage Small Cell Lung Cancer1HCC1KRAS Gene Mutation1Lung Cancer Squamous Cell1Lung Cancer Stage II1Lung Cancer Stage IV1Lung Disease1Neoplasms1Neoplasms by Site1Non Small Cell Lung Cancer1Non-small Cell Lung Cancer1NSCLC Stage IV1
Leading sponsors
Jiangsu HengRui Medicine Co., Ltd.7Cancer Institute and Hospital, Chinese Academy of Medical Sciences1Harbin Medical University1Shandong Cancer Hospital and Institute1Shanghai Pulmonary Hospital, Shanghai, China1Sichuan Cancer Hospital and Research Institute1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1Sun Yat-sen University1Xuanwu Hospital, Beijing1
Trial status mix
UNKNOWN9
COMPLETED4
TERMINATED2
Phase mix
PHASE212
PHASE13
PHASE32
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.